| Melissa Gold O'neal, MD | |
|
104 Medical Dr, Williamston, NC 27892-2156 | |
| (252) 809-6341 | |
| (252) 809-6376 |
| Full Name | Melissa Gold O'neal |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 25 Years |
| Location | 104 Medical Dr, Williamston, North Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366411209 | NPI | - | NPPES |
| C8684 | Other | NC | MEDCOST |
| 8913447 | Medicaid | NC | |
| 13447 | Other | NC | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 200300858 (North Carolina) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Vidant Medical Group Llc | 0345343893 | 849 |
News Archive
The scientific poster session, Interventions for the Treatment and Prevention of Nutrition-Related Diseases, included the poster that won first prize in two American Society for Nutrition Scientific Sessions at Experimental Biology contests- the Student Interest Group Travel Award competition and the Aging and Chronic Disease Research Interest Section Graduate Student Poster competition.
Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson's disease.
Masimo announced today the findings of a study in which researchers evaluated the ability of Masimo ORi™ to detect declining blood oxygenation prior to standard oxygen saturation monitoring in patients undergoing elective thoracic surgery requiring one-lung ventilation
Celgene today announced that data from the FIRST (Frontline Investigation of lenalidomide and dexamethasone vs. standard thalidomide) trial was presented on Sunday 8 December, during the Plenary Scientific Session at the 55th American Society Hematology annual meeting in New Orleans. FIRST (MM-020/IFM 07-01) a phase III, multi-centre study in patients newly diagnosed with multiple myeloma and ineligible for stem cell transplant, included 72 patients from the UK.
› Verified 5 days ago
| Entity Name | Williamston Clinic Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811990443 PECOS PAC ID: 6709790082 Enrollment ID: O20031119000708 |
News Archive
The scientific poster session, Interventions for the Treatment and Prevention of Nutrition-Related Diseases, included the poster that won first prize in two American Society for Nutrition Scientific Sessions at Experimental Biology contests- the Student Interest Group Travel Award competition and the Aging and Chronic Disease Research Interest Section Graduate Student Poster competition.
Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson's disease.
Masimo announced today the findings of a study in which researchers evaluated the ability of Masimo ORi™ to detect declining blood oxygenation prior to standard oxygen saturation monitoring in patients undergoing elective thoracic surgery requiring one-lung ventilation
Celgene today announced that data from the FIRST (Frontline Investigation of lenalidomide and dexamethasone vs. standard thalidomide) trial was presented on Sunday 8 December, during the Plenary Scientific Session at the 55th American Society Hematology annual meeting in New Orleans. FIRST (MM-020/IFM 07-01) a phase III, multi-centre study in patients newly diagnosed with multiple myeloma and ineligible for stem cell transplant, included 72 patients from the UK.
› Verified 5 days ago
| Entity Name | Vidant Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477648731 PECOS PAC ID: 0345343893 Enrollment ID: O20070321000445 |
News Archive
The scientific poster session, Interventions for the Treatment and Prevention of Nutrition-Related Diseases, included the poster that won first prize in two American Society for Nutrition Scientific Sessions at Experimental Biology contests- the Student Interest Group Travel Award competition and the Aging and Chronic Disease Research Interest Section Graduate Student Poster competition.
Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson's disease.
Masimo announced today the findings of a study in which researchers evaluated the ability of Masimo ORi™ to detect declining blood oxygenation prior to standard oxygen saturation monitoring in patients undergoing elective thoracic surgery requiring one-lung ventilation
Celgene today announced that data from the FIRST (Frontline Investigation of lenalidomide and dexamethasone vs. standard thalidomide) trial was presented on Sunday 8 December, during the Plenary Scientific Session at the 55th American Society Hematology annual meeting in New Orleans. FIRST (MM-020/IFM 07-01) a phase III, multi-centre study in patients newly diagnosed with multiple myeloma and ineligible for stem cell transplant, included 72 patients from the UK.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melissa Gold O'neal, MD 7100 Commerce Way, Suite 180, Brentwood, TN 37027-2829 Ph: (615) 465-7000 | Melissa Gold O'neal, MD 104 Medical Dr, Williamston, NC 27892-2156 Ph: (252) 809-6341 |
News Archive
The scientific poster session, Interventions for the Treatment and Prevention of Nutrition-Related Diseases, included the poster that won first prize in two American Society for Nutrition Scientific Sessions at Experimental Biology contests- the Student Interest Group Travel Award competition and the Aging and Chronic Disease Research Interest Section Graduate Student Poster competition.
Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson's disease.
Masimo announced today the findings of a study in which researchers evaluated the ability of Masimo ORi™ to detect declining blood oxygenation prior to standard oxygen saturation monitoring in patients undergoing elective thoracic surgery requiring one-lung ventilation
Celgene today announced that data from the FIRST (Frontline Investigation of lenalidomide and dexamethasone vs. standard thalidomide) trial was presented on Sunday 8 December, during the Plenary Scientific Session at the 55th American Society Hematology annual meeting in New Orleans. FIRST (MM-020/IFM 07-01) a phase III, multi-centre study in patients newly diagnosed with multiple myeloma and ineligible for stem cell transplant, included 72 patients from the UK.
› Verified 5 days ago
Melissa Greene, CNM Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 104 Medical Dr, Williamston, NC 27892 Phone: 252-809-6341 |